These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23811060)

  • 1. Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.
    Wilcox CE; Bogenschutz MP; Nakazawa M; Woody G
    Addict Behav; 2013 Oct; 38(10):2568-74. PubMed ID: 23811060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compensation effects on clinical trial data collection in opioid-dependent young adults.
    Wilcox CE; Bogenschutz MP; Nakazawa M; Woody GE
    Am J Drug Alcohol Abuse; 2012 Jan; 38(1):81-6. PubMed ID: 21936751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
    Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
    Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
    Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
    J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
    Ling W; Amass L; Shoptaw S; Annon JJ; Hillhouse M; Babcock D; Brigham G; Harrer J; Reid M; Muir J; Buchan B; Orr D; Woody G; Krejci J; Ziedonis D;
    Addiction; 2005 Aug; 100(8):1090-100. PubMed ID: 16042639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.
    Warden D; Subramaniam GA; Carmody T; Woody GE; Minhajuddin A; Poole SA; Potter J; Fishman M; Bogenschutz M; Patkar A; Trivedi MH
    Addict Behav; 2012 Sep; 37(9):1046-53. PubMed ID: 22626890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
    Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
    Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
    Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
    J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
    Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD
    Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.
    Bagley SM; Cheng DM; Winter M; Alford DP; LaBelle C; Walley AY; Samet JH
    Drug Alcohol Depend; 2018 Nov; 192():245-249. PubMed ID: 30290291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders.
    Hammond CJ; Park G; Kady A; Rathod K; Rahman N; Vidal C; Wenzel K; Fishman M
    J Subst Abuse Treat; 2022 Feb; 133():108495. PubMed ID: 34218992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.